Literature DB >> 29174730

How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry.

F Alcaide1, J Amlerová2, G Bou3, P J Ceyssens4, P Coll5, D Corcoran6, M-S Fangous7, I González-Álvarez8, R Gorton9, G Greub10, G Hery-Arnaud7, J Hrábak2, A Ingebretsen11, B Lucey12, I Marekoviċ13, C Mediavilla-Gradolph14, M R Monté15, J O'Connor12, J O'Mahony12, O Opota16, B O'Reilly6, D Orth-Höller17, M Oviaño3, J J Palacios8, B Palop14, A B Pranada18, L Quiroga19, D Rodríguez-Temporal1, M J Ruiz-Serrano20, G Tudó15, A Van den Bossche4, J van Ingen21, B Rodriguez-Sanchez22.   

Abstract

BACKGROUND: The implementation of MALDI-TOF MS for microorganism identification has changed the routine of the microbiology laboratories as we knew it. Most microorganisms can now be reliably identified within minutes using this inexpensive, user-friendly methodology. However, its application in the identification of mycobacteria isolates has been hampered by the structure of their cell wall. Improvements in the sample processing method and in the available database have proved key factors for the rapid and reliable identification of non-tuberculous mycobacteria isolates using MALDI-TOF MS. AIMS: The main objective is to provide information about the proceedings for the identification of non-tuberculous isolates using MALDI-TOF MS and to review different sample processing methods, available databases, and the interpretation of the results. SOURCES: Results from relevant studies on the use of the available MALDI-TOF MS instruments, the implementation of innovative sample processing methods, or the implementation of improved databases are discussed. CONTENT: Insight about the methodology required for reliable identification of non-tuberculous mycobacteria and its implementation in the microbiology laboratory routine is provided. IMPLICATIONS: Microbiology laboratories where MALDI-TOF MS is available can benefit from its capacity to identify most clinically interesting non-tuberculous mycobacteria in a rapid, reliable, and inexpensive manner.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Keywords:  Identification; MALDI-TOF MS; Non-tuberculous mycobacteria; Procedure; Sample preparation

Mesh:

Year:  2017        PMID: 29174730     DOI: 10.1016/j.cmi.2017.11.012

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  21 in total

1.  Evaluation of MALDI Biotyper Interpretation Criteria for Accurate Identification of Nontuberculous Mycobacteria.

Authors:  David Rodriguez-Temporal; Belén Rodríguez-Sánchez; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

2.  Surgical site infections by atypical mycobacteria: prevalence and species characterization using MALDI-TOF and molecular LCD chip array.

Authors:  Maha A Gad; Sahar M Khairat; Amira M A Salama; Omnia A Abd Elmoez; Noha S Soliman
Journal:  Infection       Date:  2022-06-18       Impact factor: 3.553

3.  Microbial Identification in the Clinical Microbiology Laboratory Using MALDI-TOF-MS.

Authors:  Iván Bloise; M Teresa Corcuera; Julio García-Rodríguez; Jesús Mingorance
Journal:  Methods Mol Biol       Date:  2022

4.  Evaluation of MALDI Biotyper Mycobacteria Library for Identification of Nontuberculous Mycobacteria.

Authors:  Nadege C Toney; Wenming Zhu; Bette Jensen; Jarrett Gartin; Karen Anderson; David Lonsway; Maria Karlsson; J Kamile Rasheed
Journal:  J Clin Microbiol       Date:  2022-08-15       Impact factor: 11.677

5.  Mycobacterium chimaera Identification Using MALDI-TOF MS Technology: A Practical Approach for the Clinical Microbiology Laboratories.

Authors:  Jessica Bagnarino; Daniela Barbarini; Giuseppe Russello; Mariangela Siciliano; Vincenzina Monzillo; Fausto Baldanti; Edoardo Carretto
Journal:  Microorganisms       Date:  2022-06-09

6.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

7.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

8.  Mycobacterium avium: an Emerging Pathogen for Dog Breeds with Hereditary Immunodeficiencies.

Authors:  Giovanni Ghielmetti; Urs Giger
Journal:  Curr Clin Microbiol Rep       Date:  2020-08-18

9.  Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018.

Authors:  Belén Rodríguez-Sánchez; Emilia Cercenado; Alix T Coste; Gilbert Greub
Journal:  Euro Surveill       Date:  2019-01

10.  Performance of lipid fingerprint-based MALDI-ToF for the diagnosis of mycobacterial infections.

Authors:  Ximena Gonzalo; Agnieszka Broda; Francis Drobniewski; Gerald Larrouy-Maumus
Journal:  Clin Microbiol Infect       Date:  2020-08-27       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.